Telix Pharmaceuticals is trading 5.91% down at $10.50 in pre-market following its Q3 2026 update; reporting does not establish the update as the cause of the decline.

  • Shares fell from the October 20 close of $11.16.
  • Q3 group revenue was US$245 million, up 19% year over year but down 1% from Q2.
  • Telix reaffirmed its FY2026 outlook and narrowed its R&D spending guidance range; broader market indicators provided were modestly positive.